These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 11689387)

  • 21. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
    Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients.
    Barton Pai A; Lin S; Arruda JA; Lau AH
    Int J Artif Organs; 2003 Jun; 26(6):484-90. PubMed ID: 12866654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
    Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
    Martin KJ; González EA; Gellens ME; Hamm LL; Abboud H; Lindberg J
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.
    Seeherunvong W; Nwobi O; Abitbol CL; Chandar J; Strauss J; Zilleruelo G
    Pediatr Nephrol; 2006 Oct; 21(10):1434-9. PubMed ID: 16900383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.
    Shuja SB; Raja RM
    Adv Perit Dial; 2003; 19():231-5. PubMed ID: 14763069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.
    Sprague SM; Lerma E; McCormmick D; Abraham M; Batlle D
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S51-6. PubMed ID: 11689388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients.
    Zheng JQ; Hou YC; Zheng CM; Lu CL; Liu WC; Wu CC; Huang MT; Lin YF; Lu KC
    Nutrients; 2016 Nov; 8(11):. PubMed ID: 27827962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
    Večerić-Haler Ž; Romozi K; Antonič M; Benedik M; Ponikvar JB; Ponikvar R; Knap B
    Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD).
    Miedziaszczyk M; Idasiak-Piechocka I; Wiśniewski OW; Lacka K
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):232-239. PubMed ID: 35049000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
    J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of calcitriol on secondary hyperparathyroidism].
    Xu H; Zhang J; Cheng X; Zhou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
    Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
    J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients.
    Zawierucha J; Małyszko J; Małyszko JS; Prystacki T; Marcinkowski W; Dryl-Rydzyńska T
    Pol Arch Intern Med; 2017 Dec; 127(12):840-845. PubMed ID: 29067991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.